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Abstract
Introduction: Chronic cerebral ischemia (CCI) accounts for 60-75% of all cerebrovascular diseases in Russia and 
around the world. The problem: the issues concerning the role of immunity in the pathogenesis of CCI depending 
on the main etiologic factor and stage of the disease are hardly elaborated, which makes the main pharmacological 
correction impossible. The objective of the study is to establish the immune disorder patterns in patients with CCI 
I-II associated with arterial hypertension and to develop differentiated pharmacological methods for their correction. 
Material and methods: The results of treatment of 104 patients of Kursk Regional Clinical Hospital with CCI as-
sociated with II-stage arterial hypertension were analyzed: 52 patients were with CCI I stage (2th-4th groups of 12-14 
patients) and 52 patients were with CCI II stage (5th -7th groups of 12-14 patients), aged 50±5, who received the basic 
pharmacological therapy (enalapril and vinpocetine). The patients of the 2nd and 5th groups additionally received cerax-
on and mexicor, those of the 3rd and the 6th groups additionally received immunomodulator glutoxim, and those from 
the 4th and 7th groups received polyoxidonium. Twenty-two healthy donors were in the control group. Immune disorders 
were assessed by the parameters of the functional activity of neutrophils, levels of cytokines in plasma, components of 
the complement and inhibitors. 
Results and discussion: In the case of CCI I and II stages similar proinflamatory immune disorders were detected, 
which is indicative of immune inflammation. The inclusion of glutoxime and polyoxidonium in a complex pharma-
cotherapy helps reduce the severity of immune and neuropsychic status indicators, which are more evident in case of 
stage II.
Conclusions: In case of CCI I stage, the medications used can be arranged according to their clinico-immunological 
efficacy in ascending order: ceraxon+mexicore ® ceraxon+mexicor+glutoxim ® ceraxon+mexicor+polyoxidonium, and 
in case of CCI II stage: ceraxon+mexicor ® ceraxon+mexicor+polyoxidonium = ceraxon+mexicor+glutoxim.
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Introduction
At present, cerebrovascular diseases are viewed as some 
of the most pressing social and medical problems and 
even as an “epidemic of the XXI century”. Late diagno-
sing, prophylaxis and treatment of vascular diseases can 
lead to disease progression and the development of severe 
dysfunctions of the brain, which in turn results in labor 
and social disadaptation of patients. Among the various 
neurological symptoms observed in this category of pa-
tients, of crucial importance are cognitive dysfunctions, 
as it is their appearance that largely determines a decrease 
in the quality of patients’ life. According to their clinical 
manifestations, vascular cognitive disorders are quite he-
terogeneous, which can be explained, on the one hand, by 
different localization of brain damaged areas, and, on the 
other hand, by differences in developing cognitive defi-
cit. Vascular cognitive disorders, including both dementia 
and non-dementia forms of cognitive decline, are obser-
ved in 2.8-10% of people over 65 years of age (Zakharova 
et al. 2014, Levin 2012, Litvinenko et al. 2013, Tanashyan 
et al. 2016, Wancata et al. 2016). 
In Russia, as well as in the whole world, cerebrovas-
cular diseases ranked second both in the structure of mor-
tality caused by circulatory system diseases and in the 
overall mortality of the population, with chronic cerebral 
ischemia (CCI) accounting for 60-75% of all cerebrovas-
cular diseases. Now people over 65 years of age make up 
to 10-15% of the population, and this figure is expected to 
reach 20-25% in 20 years, with the number of people over 
80 to increase most rapidly, and their number in the next 
decade may increase 3 times. A strong trend of the last 
10-15 years has also been that the contingent of patients 
with various types of cerebrovascular diseases has beco-
me much younger, which results from a constant incre-
ase in the impact of unfavorable external factors and low 
effectiveness of programs to prevent socially significant 
diseases, primarily atherosclerosis and arterial hyperten-
sion (AH) (Zakharova et al. 2014, Skvortsova et al. 2008, 
Kadykov et al. 2014, Mitra et al. 2011).
In the Russian literature, the following terms are most 
frequently used to refer to clinical signs of CCI: chronic 
cerebral circulatory insufficiency, dyscirculatory encep-
halopathy, chronic cerebrovascular disease, etc. All these 
are a variety of cerebral vascular pathology with a slow-
ly progressing diffuse damage to the blood supply to the 
brain and increasing various functioning defects. CCI is 
clinically manifested by a complex of neurological and 
psychiatric syndromes, the most usual being such subjec-
tive manifestations as headache, dizziness, tinnitus, and 
fast fatigue. The core of the clinical picture that determi-
nes the severity of patients’ condition is an increased limi-
tation of cognitive and motor functions. Further cognitive 
impairment may develop into vascular dementia (Levin et 
al. 2014, Roman et al. 2002, Ovesgharan and Hachinski 
2010). CCI is, on the one hand, a risk factor for stroke, 
and, on the other hand, is a cause of a gradual increase 
in neurological and psychiatric disorders, a slowly pro-
gressing damage to cerebral circulation of a multifocal or 
diffuse nature, resulting from the gradual accumulation of 
ischemic and secondary degenerative changes in the brain 
caused by recurrent ischemic episodes. The manifestati-
ons of this disease, depending on the stage of the process, 
can vary from subclinical phenomena to the signs of per-
sistent neurological deficit combined with emotional-per-
sonal and cognitive disorders (O’Brien et al. 2003, Xu et 
al. 2004).
The main etiological factors leading to neurologic ma-
nifestations in CCI patients are determined by two fac-
tors: AH, cerebral atherosclerosis and their combination. 
In accordance with these views, several forms of CCI are 
distinguished: hypertonic form, which can manifest itself 
as sub-cortical arteriosclerotic encephalopathy and hy-
pertensive multi-infarct encephalopathy; atherosclerotic 
form and mixed forms. Less common are CCI forms as-
sociated with other diseases (diabetes, metabolic syndro-
me, systemic diseases, anti-phospholipid syndrome, etc.) 
(Zakharova et al. 2014, Tanashyan et al. 2016, Gusev and 
Chukanova 2015, Roger et al. 2012).
In the pathogenesis of CCI formation, a crucial role is 
played by long-term cerebral hypoperfusion, due to lo-
cal stenoses of cerebral arteries and other mechanical ob-
structions to the blood flow, micro- and macroangiopathy. 
Pathology of small cerebral arteries (cerebral microangio-
pathy), affecting primarily the longest penetrating medul-
lary arteries of the cerebral hemispheres and brainstem. 
The main cause of cerebral microangiopathy is AH, less 
frequent causes of damage to small cerebral arteries being 
amyloid angiopathy, hereditary and inflammatory vas-
culopathies. Antemortem verification of small vascular 
lesions is not always possible, but their consequences – 
leukoencephalopathy, lacunar status, microinfarcts, mi-
cro-hemorrhaging, secondary cerebral atrophy, etc. – can 
be detected through neuroimaging (O’Brien et al. 2003, 
Gusev and Chukanova 2015, Zakharov et al. 2016, Panto-
ni et al. 2007, Cordonnier et al. 2006).
An cruicial role in the development of CCI is also play-
ed by the dysfunction of neurovascular units that unite 
neurons, astrocytes and cells of the vascular wall into a 
single functional system. The dysfunction of neurovascu-
lar units leads to the failure of cerebral autoregulation me-
chanisms, accompanied by the damage to the blood-brain 
barrier. One of the most important parts of this process is 
the development of oxidative stress and endothelial dys-
function in small vessels, which results in their decreased 
reactivity and a deficiency in perfusion of the functional-
ly active areas of the brain (Gusev and Chukanova 2015, 
Girouard and Iadecola 2006, Farrall and Wardlaw 2009).
AH contributes both to the development and progres-
sion of CCI. There is increasing evidence that AH is the 
most powerful modifiable risk factor for developing ce-
rebral vascular dysfunction and can result in a gradual 
decrease in cognitive functions (Gavrilyuk et al. 2016, 
Jellinger and Attems 2010, Nelson et al. 2011).
As is known, the nature of an immune response and 
patterns of pathophysiological changes in case of ische-
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mic/hypoxic tissue disorders depend on preferential acti-
vation of subpopulations of T-lymphocytes, their synthe-
sizing cytokines of various types and forming a “cytokine 
cascade”, namely a ratio of pro-inflammatory and anti-in-
flammatory cytokines (Ketlinsky and Simbirtsev 2008). 
In recent years, an increasing number of facts have been 
accumulated about an important role of the immune sys-
tem in cerebrovascular pathology, for example, in the 
pathogenesis of atherosclerosis and arterial hypertensi-
on, which are essential for emergence and progression of 
CCI, the key role is played by the immuno-inflammatory 
mechanisms. Cytokines of T-helper (Th1) lymphocytes 
– IL-2, IFNγ, as well as chemokines macrophage, espe-
cially MCP-1, are considered as pro-atherogenic, whe-
reas cytokines Th2 (IL-4, IL-5, IL- 10, IL-13) play an 
anti-atherogenic role (Zurochka et al. 2013, Voronina et 
al. 2014). AH-induced chronic ischemization of brain tis-
sues causes immune inflammation and lipid metabolism 
disorder, which leads to irreversible damage to phospho-
lipid membrane complexes and a destructive process in 
neuroglia (Gavrilyuk et al. 2016, Kamchatnov et al. 2016, 
Menshikov et al. 2010).
Problem
In clinical practice, neurological and sometimes mental 
disorders reflecting brain dysfunction in senior patients, 
especially those suffering from cardiovascular diseases, 
are attributed to, which results in overdiagnosis the di-
sease, which, in turn, leaves its diagnosis and treatment 
insufficiently developed and questions the effectiveness 
of some vasoactive drugs widely used in clinical practice. 
Moreover, to evaluate the effect of treating CCI, no mo-
dern clinical and psychometric research scales have been 
applied, and the diagnosis has never been verified by mo-
dern neuropsychological and neuroimaging methods (Gu-
sev and Chukanova 2015, Zakharov et al. 2016).
The literature quite comprehensively covers the issues 
of the involvement of immune mechanisms in the onset 
and development of atherosclerosis, AH, acute forms 
of cerebrovascular pathology, but there are a number of 
open issues concerning the role of immunity in the patho-
genesis of CCI, depending on the main etiologic factor 
and a stage of the disease, which prevents the relevant 
pathogenetic pharmacological correction (Gavrilyuk et al. 
2016, Menshikov et al. 2010, Turmova et al. 2014, Tabee-
va 2015, Libby et al. 2011).
Improving the understanding of the pathogenesis of 
CCI is of great importance for selecting the main di-
rections for pharmacological correction of disorders. In 
accordance with this, apart from a vasotropic therapy, 
elimination of causes of microangiopathies (arterial hy-
pertension, diabetes, etc.), correction of endothelial dys-
function, oxidative stress, provision of neuroprotection, 
on the agenda is the application of immunomodulators to 
correct immune disorders in the early stages of the disease 
(Zakharova et al. 2014, Skvortsova et al. 2008, Zurochka 
et al. 2013, Vorobyova et al. 2010).
It is logical to assume that detecting and correcting 
immune disorders in case of CCI of hypertensive origin 
may affect the severity of neurological symptoms. In this 
regard, studies on the state of the immune (the cytokine 
and complement system, immunoglobulins) and metabo-
lic parameters (lipid peroxidation, antioxidant defense, 
stable metabolites of nitric oxide) are of relevance. This 
circumstance is also emphasized in the Order of the Mi-
nistry of Healthcare of Russia No. 281 of 30 April 2013 
on the expediency of developing new methods for early 
diagnosis and a personified approach to the treatment ba-
sed on studying neurohumoral and immune mechanisms 
of cardiovascular disease development.
Thus, the development of a pharmacological strategy 
for correcting immune system disorders in case of acute 
and chronic ischemic damage to the brain is one of the 
urgent problems of modern medicine.
Objective: to establish the patterns of immune disor-
ders in patients with CCI I-II associated with arterial hy-
pertension and to develop differentiated pharmacological 
methods for their correction. 
Materials and methods
During 2014–2017 (retrospectively), under outpatient 
observation there were 120 patients with CCI associated 
with II-degree II-stage arterial hypertension risk 2, who 
received an antihypertensive therapy, including β-adreno-
blockers, calcium antagonists, angiotensin-converting en-
zyme inhibitors, and diuretics.
The prospective study included 104 patients, of whom 
76 female and 28 male patients made up the main group 
of those hospitalized in the neurological department of 
Kursk Regional Clinical Hospital with arterial pressure 
corrected to the target level, with CCI associated with hy-
pertension, of whom 52 patients were with CCI I stage (1st 
main group) and 52 patients with CCI II stage (2nd main 
group) aged 50±5.
The patients were included into the study basing on 
informed consent and the decision of the regional ethics 
committee.
In addition, the clinical and laboratory indicators of 22 
healthy donors (aged 52±2) that formed the control group 
1 were studied; the obtained data are accepted as a con-
ditional norm.
The criteria for including patients into the main group 
were: age from 40 to 60 years; absence of concomitant 
diseases in the acute stage, having CCI on the background 
of II-degree II-stage hypertension risk 2, which had been 
diagnosed 5 or more years ago in accordance with the 
recommendations of the World Health Organization and 
the International Society for Hypertension (ISH, 1999). 
The diagnosis of II-stage CCI is substantiated by a set of 
clinical and imaging symptoms: 1) impaired well-being; 
2) organic cerebral focal symptoms in the form of vesti-
bulo-atactic, cerebellar, pyramidal, pseudobulbar syndro-
mes; 3) syndrome of cognitive dysfunction; 4) a vascular 
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profile of changes in the brain according to magnetic reso-
nance imaging (MRI) in the form of leukoarose, lacunar 
foci, internal mild and moderate hydrocephalus.
Exclusion criteria were: hemodynamically significant 
stenoses of brachiocephalic and cerebral vessels, distur-
bances in the cardiac rhythm and conduction; heart defects; 
myocardial infarction, postinfarction cardiosclerosis and 
progressive angina pectoris, or their presence in the anam-
nesis; symptomatic arterial hypertension; chronic cardiac 
failure above NYHA class II; diabetes mellitus or impaired 
glucose tolerance; significant or moderate atherosclerotic 
changes in the vessels of the eyeground. 
All patients underwent a complex clinical and instru-
mental examination according to the generally accepted 
standards, and in all cases the diagnosis of the I- and II-stage 
CCI was verified. 
The examination methods included a clinical assess-
ment of the neurological status; the severity of cognitive 
impairment was assessed by the Global Deterioration Ra-
ting scale (Folstein et al. 1975), the Montreal Cognitive 
Scale (MoCA), MRI of the brain (Philips apparatus, with 
magnetic intensity of 0.3 Tesla). All the examined sub-
jects received consultation from an ophthalmologist and 
a cardiologist.
Assessment of clinical and laboratory data and a 
neurological status in the main group was undertaken at 
the beginning and two weeks after the treatment. Evalua-
tion of cognitive dysfunction was carried out two months 
after the comprehensive treatment (in the main group). To 
objectify and unify the assessment of changes in the well-
being and neurological status, there was used a rating sca-
le developed by the authors to determine the severity of 
the disorders (Shulginova et al. 2014, Shulginova et al. 
2015).
The treatment was consistent with the principles of 
evidence-based medicine, all the patients were on a nitra-
te-free diet. 
All the patients in the main groups received a basic 
pharmacological therapy every day for 14 days: an an-
giotensin-converting enzyme inhibitor enalapril maleate 
(Berlipril), (supporting antihypertensive therapy) and a 
vasoactive drug – ethyl ester of apovincamic acid (Bra-
vinton, Vinpocetine, Vincetin, Cavinton).
The study design and the drugs that the patients of the 
main groups received are shown in Table 1.
The used pharmacological preparations and the 
schemes of their administration in patients with CCI are 
shown in Table 2. All the drugs were administered ac-
cording to the recommendations described in the refer-
ence book “Lekarstvennye sredstva (Medicines)” (Mash-
kovskiy M.D., 2001) and the instructions and annotations 
attached thereto. 
Assessment of clinical and laboratory data in the main 
groups was performed at the beginning of the treatment 
and two weeks after the end of the treatment. 
Cytokines (TNFα, IL-1β, IL-6, IL-8, IFNγ, IL-2, IL-
17, IL-18, G-CSF, IL-4, IL-10, IL-1RA) were detected by 
solid-phase ELISA using kits made by Vector-Best (Rus-
sia), components of the complement system (C3, C3a, C4, 
C5, C5a) and factor H by the diagnostic kit made by  Cy-
tokine Ltd. (Russia). The activity of the C1-inhibitor was 
determined by the chromogenic method by its ability to 
inhibit C1-esterase. The registration of all ELISA results 
was carried out using a microplate reader “Sunrise”, Te-
can (Austria). 
The phagocytic activity of polymorphonuclear leu-
kocytes after their isolation from blood on a Ficoll-Uro-
grafin gradient (with d = 1,077) was evaluated according 
to the standard procedure determining phagocytic index 
(PI), phagocytic number (PN), and the phagocytosis ac-
tivity index (PAI). The activity of oxygen-dependent neu-
trophil systems was evaluated using a spectrophotometer 
PD-303 (Apel, Saitama, Japan) basing on the reduction 
reaction of nitroblue tetrazolium (NBT-test), spontaneous 
and stimulated with zymosan (NBT-sp, NBT-st), the neu-
trophil stimulation index (SI) and the neutrophil function-
al reserve (FR).
Statistical processing of the study results was carried 
out according to the criteria of the variance statistical 
analysis with computing of the mean (M), the the arith-
metic mean error (m) with the help of the Microsoft Excel 
software package, 2010. The significance of difference 
was assessed by the U-criterion. Differences with p <0.05 
were considered statistically significant.
Results and discussion
The original purpose of the study was to detect immune 
disorders in patients with associated with hypertension 
depending on the stage of the disease.
Before starting the treatment, an increased concentra-
tion of proinflammatory cytokines was detected in blood 
plasma of the patients: TNFα, IL-1β, IL-6, IL-8, IL-17 
and IL-18, an increase being 4.4, 2.4, 5.5, 5.9, 1.2, and 
2.6 times, respectively, of anti-inflammatory cytokines: 
IL-4, IL-10 and IL-1RA with an increase of 8.0, 1.4 and 
1.1 times, respectively. The content of IFNγ, IL-2, and 
G-CSF growth factor turned out to be 1.4, 45.0 and 1.7 
times higher than the parameters of the healthy donors, 
respectively (Table 3).
In case of CCI II stage, the similarly oriented changes 
in the content of cytokines were revealed in blood plasma. 
The levels of TNFα, IL-1β, IL-6, IL-8, IL-17 and IL-18 
turned out to have increased 5.2, 2.1, 5.8, 9.0, 2.6 and 2.8 
times, respectively. The content of IL-4, IL-10 and IL-
1RA increased correspondingly 20.0, 1.4 and 1.2 times, 
and that of IFNγ, IL-2 and G-CSF increased 1.5, 48.6 and 
1.9 times (Table 3).
In blood plasma of the patients with I and II stage of 
CCI before starting the treatment, a decrease in the con-
tent of C3 and C5-components of the complement, C1-in-
hibitor, an increase in C3a and C5a components was de-
tected, while the level of C
4
 remained within the normal 
range. The concentration of the inhibitor-factor H in case 
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Table 1. Distribution of patients by the method of administered pharmacotherapy
Patients Group Pharmacotherapy Count
Basic pharmacological therapy Berlipril, Cavinton 104
CCI – I stage
1 Cereton and Actovegin 12
2 Ceraxon and Mexicore 12
3 Ceracson, Mexicor and Glutoxim 14
4 Ceracson and Mexicor and Polyoxidonium 14
CCI – II stage
1 Cereton and Actovegin 12
2 Ceraxon and Mexicore 12
3 Ceracson, Mexicor and Glutoxim 14
4 Ceracson and Mexicor and Polyoxidonium 14
Total 104
Donors 22
Table 2. Drugs administered and drug dosage regimens for patients with CCI
Drug name Drug dosage regimens
Basic pharmacotherapy
BERLIPRIL 10 mg a day orally, in 
24 hours № 14Latin name: Berlipril
International name – Enalarpil
Trade names: Enalapril, Bagopril®, Berlipril® Vasoprene, Invoril®, Renipril®, Renitec, Ednit, Enalapril 
maleate, Enam®, Enap®, Enarenal®, Enafarm, Envas, Enipril
Chemical name: (S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline (as maleate)
Drug form: tablets
Manufacturer: Berlin-Chemie AG/Menarini Group (Germany), Berlipril® plus. Closed Actioner Sosety 
Berlin-Farma, Russia
Identification Number: П №012342/01-2000 25.10.00ППР 
Pharmacotherapeutic group: ACE inhibitors
VINPOCETINE 10 mg in 200,0 ml 0,9% 
solution of sodium 
chloride intravenously, 
by drop infusion, in 24 
hours № 14
Latin name: Vinpocetinum
International non-proprietary name (established name): Vinpocetine
Brand name: Vinpocetine
Chemical name: ethyl-(3alpha, 16alpha)-eburnamene-14-carboxylate
Drug form: tablets, infusion solution
Manufacturer: Closed Actioner Sosety Sotex Pharm Firma, Russia
Identification number: R N003245/01 (2030-06-09– 0000-00-00)
Pharmacotherapeutic group: cerebral blood flow improver
Immunomodulators
POLYOXIDONIUM 6 mg (intramuscularly), 
8 times (daily for the 
first 2 days, then every 
second day)
Latin name: Polyoxidonium
International non-proprietary name (established name): Аzoximeri bromidum
Brand name: Polyoxidonium®
Chemical name: copolymer of 1,4-ethylene-piperazine N-oxide and (N-carboxymethyl)-1,4-ethylene-
piperazinium bromide
Drug form: vaginal and rectal suppositories, tablets, injection solution and drop solution
Manufacturer: NPO Petrovax Farm, Russia
Identification number: R N002935/04
Pharmacotherapeutic group: immunomodulator 
GLUTOXIM 30 mg in 1 ml 
of 3% solution, 
intramuscularly, in 24 
hours № 14
Latin name: Glutoxim
International non-proprietary name (established name): Glutamyl-Cysteinyl-Glycine Disodium
Brand name: Glutoxim®
Chemical name: bis-(gamma-L-glutamyl)-L-cysteinyl-bis-glycine disodium salt
Drug form: injection solution
Manufacturer: Closed Actioner Sosety Farma Vam, Russia
Identification number: R N002010/01-290908
Pharmacotherapeutic group: immunostimulator 
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Drug name Drug dosage regimens
Antioxidants/antihypoxants
MEXICORE 200 mg in 24 hours, 
intramuscularly, stream 
infusion for 5 min, № 14
Latin name: Mexicor
International non-proprietary name (established name): Ethyl methylhydroxypyridine succinate 
(Ethylmethylhydroxypyridine succinate)
Brand name: Mexidol®, Ethylmethylhydroxypyridine succinate, Mexifin®, Mexident®Mexicor®, Mexipur
Chemical name: 2-ethyl-6-methyl-3-hydroxypyridine succinate
Drug form: capsules, intravenous and intramuscular solutions
Manufacturer: OOO EcoPharmInvest, Russia
Identification number: R №001245/01 (2010-09-08– 0000-00-00)
Pharmacotherapeutic group: antioxidant
ACTOVEGIN 200 mg of Actovegin 
(Nycomed Austria 
GmbH, Austria) in 5 ml, 
intramuscularly, stream 
infusion, in 24 hours 
№ 14
Latin name: Actovegin
International non-proprietary name (established name): Deproteinized calf blood haemoderivative
Brand name: Actovegin®
Chemical name: deproteinized calf blood haemoderivative
Drug form: tablets, gel, infusion and injectios solutions
Manufacturer: Closed Actioner Sosety Sotex Pharm Firma, Russia
Identification number: ЛС-001323
Pharmacotherapeutic group: antihypoxic drug, tissue regeneration stimulator
Nootropics
CERAXON 1000 mg 
intramuscularly, stream 
infusion, in 24 hours 
№ 14
Latin name: Ceraxon
International non-proprietary name (established name): Citicoline
Brand name: Ceraxon®
Drug form: tablets, intramuscular and intravenous solutions, solution for oral administration
Manufacturer: Ferrer Internacional SA (Spain)
Identification number: ЛСР-000089-250116
Pharmacotherapeutic group: nootropic
CERETON 1000 mg 
intramuscularly, stream 
infusion, in 200,0 ml 
of 0,9% solution of 
sodium chloride, in 24 
hours № 14
Latin name: Cereton
International non-proprietary name (established name): Choline Alfoscerate
Brand name: Cereton® 
Drug form: intravenous and intramuscular solutions, capsules 
Manufacturer: Closed Actioner Sosety Sotex Pharm Firma, Russia
Identification number: ЛСР-005608/09 (2013-07-09– 0000-00-00)
Pharmacotherapeutic group: nootropic
of CCI I stage did not differ from the values of the donors, 
but decreased in case of CCI II stage(Table 4).
The results of studying the functional metabolic ac-
tivity of peripheral blood neutrophils were found to be 
slightly different in the patients with CCI I stage and CCI 
II stage when admitting to hospital: no changes in the 
activity and intensity of phagocytosis (PI, PN and PAI) 
compared to those of the healthy donors, an increase in 
NBT-sp along with a decrease in SI in the patients with 
CCI I stage and an increase in case of II stage of the stud-
ied parameters of the activity of oxygen-dependent poly-
morphonuclear leukocyte systems (NBT-sp, NBT-st, FR), 
except for SI (Table 5).
Thus, out of 26 investigated parameters of immune sta-
tus in the patients with CCI I stage and CCI II stage at the 
time of admission to the clinic, 73.1% and 80.8% of the 
indicators, respectively, were different from the values of 
the healthy donors, 14 (66.7%) parameters in the patients 
with both stages of CCI were the same in size and in the 
direction of the changes, another 5 (19.2%) were identical 
in the direction. The exceptions were the markers of oxy-
gen-dependent activity of circulating neutrophils: NBT-st 
and FR were higher in patients with CCI II stage compa-
red with their normal parameters in case of CCI I stage. 
SI was found to be decreased in case of stage I with its 
normal value in case of stage II. In addition, the concen-
tration of the inhibitor of the complement system, Factor 
H, was reduced in case of CCI stage II, with its normal 
value in case of CCI I stage (Table 3–5).
For a qualitative comparison of the affected indicators, 
their analysis was carried out according to a level, with di-
viding the intensity of disorders into degrees (Zemskov et 
al. 2013). At the same time, it was revealed that the I de-
gree of disorders included 7 (26.9%) indocators, and II and 
III degrees, respectively, included 4 (15.4%) and 8 (30.8%) 
indicators, which required mandatory correction (Zemskov 
et al. 2013, Konoplya et al. 2013, Konoplya et al. 2015). 
In the group of the patients with CCI I stage and CCI II 
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Table 3. Cytokine spectrum of blood plasma in case of CCI stage I and II before treatment (M ± m)
Parameters Units 1 2 3Healthy CCI-I CCI-II
IL-17 pcg/ml 8.7±0.2 10.5±0.3*1 22.6±0.9*1,2
IL-18 pcg /ml 47.6±2.1 124.4±4.2*1 135.1±5.0*1
TNFα pcg /ml 2.9±0.07 12.9±0.3*1 13.5±0.4*1
IL-8 pcg /ml 1.8±0.06 10.6±0.5*1 16.2±0.7*1,2
IL-6 pcg /ml 2.4±0.09 13.3±0.6*1 14.2±0.5*1
IL-1β pcg /ml 5.3±0.2 12.0±0.4*1 11.3±0.3*1
IL-1RA pcg /ml 137.7±1.7 149.3±2.5*1 167.8±1.6*1,2
IL-10 pcg /ml 2.7±0.13 3.7±0.1*1 3.9±0.1*1
IL-4 pcg /ml 0.4±0.04 3.2±0.08*1 8.0±0.3*1,2
IFNγ pcg /ml 15.6±0.3 22.4±0.5*1 23.6±0.7*1
G-CSF pcg /ml 12.3±1.0 20.3±0.8*1 23.6±1.1*1,2
IL-2 pcg /ml 0.14±0.02 6.3±0.3*1 6.8±0.4*1
Note: here and in other tables: the asterisk marks significant differences in the arithmetic mean (p<0.05); figures next to the asterisk 
show in relation to indicators of which group these differences are given.
Table 4. State of the complement system in case of CCI I stage and CCI II stage before treatment (M ± m)
Parameters Units 1 2 3Healthy CCI-I CCI-II
С3 mg/dL 82.2±1.5 66.3±1.7*1 65.1±2.4*1
С3а ng/ml 38.2±2.1 47.1±0.8*1 47.3±1.9*1
С
4
mg/dL 24.0±0.5 25.1±0.9 25.8±0.7
С5 mg/dL 0.1±0.01 0.05±0.006*1 0.05±0.005*1
С
5а
ng/ml 78.4±3.5 127.4±3.1*1 127.3±4.2*1
С1-inh. ng/ml 288.5±3.0 272.5±2.3*1 274.7±2.4*1
Factor Н ng/ml 39.7±1.0 39.5±1.5 36.8±0.7*1,2
Table 5. Functional and metabolic activity of circulating blood neutrophils in CCI I stage and CCI II stage before treatment (M ± m)
Parameters Units 1 2 3Healthy CCI-I CCI-II
PI % 82.8±2.3 79.1±1.7 78.9±2.8
PN abs. 7.9±0.4 7.2±0.3 7.8±0.4
PAI – 6.6±0.4 5.7±0.5 6.4±0.3
NBT-sp % 7.5±0.4 9.9±0.1*1 11.0±1.2*1
NBT-st % 25.1±2.4 26.7±1.1 37.5±2.9*1,2
FR % 17.6±2.3 16.8±1.1 26.5±2.1*1,2
SI – 3.8±0.6 2.7±0.1*1 3.4±0.3*2
stage, 21 (80.8%) parameters were found tobe disrupted, 
of which 5 (19.2%) with the I degree, and 5 (19.2%) and 
11 (42, 3%) with II and III degrees, respectively (Table 6).
The results obtained show that in patients with CCI I 
and II stages associated with AH, there are similar chan-
ges in the parameters of the immune status, which indi-
cates the presence of immune inflammation, but at the 
same time it was established that in case of stage II of 
the disease 9 (34.6%) indicators are more evident or ra-
dically different. The latter concerns the increased indices 
of oxygen-dependent activity of circulating neutrophils in 
case of CCI II stage, which can be considered as the most 
important link in the further development of inflammation 
(Karaulov and Kalyuzhin).
When comparing the changes in the neuropsychic sta-
tus in patients with CCI I and II stages, the results obtain-
ed are shown in Table 7.
The patients with CCI I and II stages before being trea-
ted had stereotypical complaints. They were disturbed by 
intensive periodic and/or permanent cephalgia localized 
in the frontal and temporal regions; pronounced and mild 
dizziness, unsteadiness when walking, whistling and buz-
zing in the ears, weakness in the limbs; sleep disturbance, 
decreased memory and attention, emotional lability, tear-
fulness and irritability.
In case of CCI I statge, pre-treatment period was do-
minated by subjective disorders in the form of headaches, 
dizziness, emotional lability, sleep disturbance, and me-
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mory loss. In case of CCI II statge, the dominating com-
plaints were non-systemic vertigo, cephalgic syndrome 
of clearer localization, the asthenic complex symptoms 
were less prominent, while the total score was statistically 
higher than that at I stage of the disease (Table 7).
When assessing the neurological status of the patients 
prior to treatment, cerebral organic symptoms were iden-
tified that were then integrated into the following syn-
dromes: vestibulopathic, pyramidal, cerebellar, of cogni-
tive dysfunction, psychopathological, and pseudobulbar. 
The mean values of the total score of the neurological 
status with CCI I stage were 1.45±0.04, with ΙΙ stage 
2.3±0.04, which indicates an increase in the distinctive fo-
cal symptomatology. The overall assessment of cognitive 
impairment in patients with with CCI I stage according to 
the Montreal scale before treatment was 21.3±0.4, and ac-
cording to the Сognitive deterioration on Monreal scale – 
1.85±0.06 points. In case of state II of the disease, a higher 
degree of cognitive impairment was identified, as indicat-
ed by the corresponding scores: 18.8±0.7 and 2.75±0.05, 
which suggests possible mild dementia (Table 7).
Thus, incase of II stage of the disease, all the param-
eters of the neuropsychic status were more pronounced, 
but the majority of the studied immune parameters turned 
out to be identical in quantity and quality in case of both 
stages of the disease, which can mean that there is im-
mune inflammation already in case of CCI I stage, which 
requires the use of specilized immunocorrection.
In the previous description of the results, it was proved 
necessary to use in case of CCI immunomodulators in a 
complex pharmacotherapy, which includes antioxidant, 
nootropic and metabolic drugs. In this connection, we 
studied the effectiveness of immunomodulators – glutoxim 
and polyoxidonium when correcting immune and clinical 
disorders in chronic ischemia of the brain of the first stage.
In case of CCI I stage, prior to the treatment, it was 
determined that on the systemic level (circulating blood 
plasma) there was an increase in the concentration of 
pro- (TNFα, IL-1β, IL-6, IL-8, IL-17 and IL-18) and an-
ti-inflammatory cytokines (IL -4, IL-10 and IL-1RA). The 
content of IFNγ, IL-2 and growth factor G-CSF was also 
found to be higher than the parameters of the healthy do-
nors. After use in the treatment of ceraxon and mexicor, 
the concentration of IL-1β and IL-1RA normalized, IL-
10 increased even more, the level of IFNγ, IL-2, G-CSF 
and IL-4 did not change, and the content of the other 
cytokines studied shifted towards the parameters of the 
healthy donors. In the patients treated, along with cer-
axon and mexicore, with glutoxim, the concentration of 
IL-17 got normalized, compared with the previous group 
of patients; the content of TNFα, IL-6, IL-8, IL-18 and 
IL-2 got modified to an even greater extent, but not to 
reach the parameters of the norm. At the same time the 
level of anti-inflammatory cytokines (IL-4, IL-10 and IL-
1RA), IL-1β, IFNγ, G-CSF remained unchanged. The use 
of polyoxidonium, in comparison with the use of ceraxon 
and mexicor, resulted in the normalized concentration of 
TNFα and IL-17, corrected, but not up to the parameters, 
IL-6, IL-8, IL-18, IL-2 and G-CSF and even to a great-
er extent increased the content of IL-4 and IL-1RA. The 
content of IL-10 and IFNγ remained unchanged (Table 8).
It should be noted that polyoxidonium is more effec-
tive than glutoxim, because, when compared, TNFα con-
centration got normalized, IL-6, IL-8, IL-2 and G-CSF 
levels were more corrected to a greater extent, and the 
content of IL-4 and IL-1RA increased.
In patients with CCI I stage before starting the treat-
ment, in blood plasma there was determined a decrease in 
the content of C3 and C5-components of the complement, 
C1-inhibitor, and an increase in the concentration of C3a 
and C5a-components, while the level of C4 and factor H 
inhibitor remained within the normal range.
After the treatment, including ceraxon and mexicor, the 
concentration of C3 and C3a complement components was 
normalized in patients and the level of C5 and C5a was cor-
rected towards the value of healthy donors. The use of glu-
tamim additionally normalized the content of C5 comple-
ment component and the C1-inhibitor. In comparison with 
glutoxim, polyoxidonium additionally normalized the con-
centration of C5a component of the complement (Table 9).
Table 6. Changes in immune parameters in case of CCI I stage and II stage before treatment
Experimental conditions
Changed indicators Changed indicators according to degree of disorder
I II III
Abs. % Abs % Abs % Abs %
CCI I stage 19 73.1 7 26.9 4 15.4 8 30.8
CCI II stage 21 80.8 5 19.2 5 19.2 11 42.3
Table 7. Neuropsychiatric status before treatment in case of CCI I and II stages (M±m)
Parameters 1 2 3Healthy CCI-I CCI-II
Subjective disorders 0.4±0.02 2.52±0.05*1 2.85±0.06*1,2
Neurological symptoms 0 1.45±0.04*1 2.3±0.04*1,2
Cognitive deterioration on GDR scale 0.15±0.01 1.85±0.06*1 2.75±0.05*1,2
Сognitive deterioration on Monreal scale 27.1±0.3 21.3±0.4*1 18.8±0.7*1,2
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In case of CCI I stage, there was found no change in 
either activity and intensity of phagocytosis (PI, PN and 
PAI) compared with those of the healthy donors, and an 
increase in NBT-sp with a decrease in SI. The use of cer-
axon and mexicor did not change the value of finctional 
metabolic activity of polymorphonuclear leukocytes of 
peripheral blood. The use of glutoxime, in comparison 
with its absence in treatment, corrects NBT-sp, but not to 
the values of healthy donors, and the use of polyoxidoni-
um additionally normalizes SI (Table 10). 
During the comparative analysis of the neuropsychic 
status in the patients with CCI-I when using different 
treatment regimens, the results presented in Table 11 were 
obtained.
When the combination of ceraxon and mexicore was 
used in therapy, the total score intensity of subjective di-
sorders was 1.72 0.09; the total intensity score of neuro-
logic sym ptoms was 1.09±0.08, and the total score on the 
Global Disability Rate scale and on the Montreal scale 
in the group of patients with CCI-I was 1.41±0.13 and 
24.58±0.6; which indicates a positive trend when using 
these drugs. Co-administration of glutoxime with ceraxon 
and mexidol brought the scores characterizing subjec-
tive disorders closer to the values of the healthy donors 
(0.94±0.03) and normalized the indicators of cognitive 
impairment according to the Montreal scale (26.34±0.46), 
without influence on the indicators of neurological symp-
toms and cognitive impairment on the GDR scale.
More positive clinical dynamics is observed when 
using together ceraxon, mexicor and polyoxidonium, as 
in patients with CCI-I, when using this treatment regi-
men, the score of subjective disorders was normalized 
to 0.5±0.08, cognitive indicator on the Montreal scale 
to 26.51±0.57, the scores of neurologic symptoms were 
corrected towards the indicators of the healthy donors, 
but not to their level, to 0.62±0.02 and cognitive impair-
ment on the GDR scale to 1, 09±0.05 (Table 11).The ob-
tained results indicate that in patients with CCI associ-
ated with hypertensive disease, significant immune and 
clinical disorders were detected, and the treatment with 
various combinations of nootropic, antioxidant and im-
munomodulating medications did not normalize some of 
Table 8. Cytokine spectrum of blood plasma in case of CCI I stage when using glutoxime and polyoxidonium (M±m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-1
Before treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
IL-1RA pkg/ml 137.7±1.7 149.3±2.5*1 133.9±2.6*2 139.2±2  .7*2 149.2±3.0*1-4
IL-10 pkg/ml 2.7±0.13 3.7±0.1*1 8.4±0.3*1,2 8.9±0.3*1,2 8.6±0.3*1,2
IL-4 pkg/ml 0.4±0.04 3.2±0.08*1 3.2±0.2*1 3.8±0.2*1 4.7±0.5*1-3
IL-8 pkg/ml 1.8±0.06 10.6±0.5*1 6.2±0.3*1.2 3.9±0.1*1-3 2.0±0.06*2-4
IL-17 pkg/ml 8.7±0.2 10.5±0.3*1 9.5±0.2*1,2 8.8±0.2*2,3 9.0±0.3*2,3
IL-18 pkg/ml 47.6±2.1 124.4±4.2*1 94.2±4.5*1,2 55.5±1.9*1-3 60.3±5.7*1-3
TNFα pkg/ml 2.9±0.07 12.9±0.3*1 8.1±0.4*1,2 4.1±0.3*1-3 3.0±0.1*2-4
IL-1β pkg/ml 5.3±0.2 12.0±0.4*1 5.4±0.1*2 5.7±0.3*2 5.2±0.2*2
IL-6 pkg/ml 2.4±0.09 13.3±0.6*1 8.6±0.9*1.2 4.3±0.5*1-3 2.9±0.1*2-4
G-CSF pkg/ml 12.3±1.0 20.3±0.8*1 18.3±1.4*1 16.8±1.0*1 14.0±1.3*1-4
IL-2 pkg/ml 0.14±0.02 6.3±0.3*1 5.9±0.8 *1 3.2±0.4*1-3 2.4±0.2*1-4
IFNγ pkg/ml 15.6±0.3 22.4±0.5*1 22.2±0.9*1 18.3±1.1*1 22.7±1.3*1
Table 9. The complement system for CCI of the first stage against the background  of the use of glutoxime and polyoxidonium (M±m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-1
Before treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
С3 mg/dl 82.2±1.5 66.3±1.7*1 83.8±3.9*2 82.4±1.3*2 84.2±4.3*2
С
4
ng/ml 24.0±0.5 25.1±0.9 23.8±1.4 28.6±1.0 25.5±1.7*4
С5 mg/dl 0.1±0.01 0.05±0.006*1 0.07±0.005*1,2 0.09±0.02*2 0.11±0.01*2,3
С
3а
mg/dl 38.2±2.1 47.1±0.8*1 40.3±2.6*2 36.1±0.9*2,3 44.4±3.2*2,4
С
5а
ng/ml 78.4±3.5 127.4±3.1*1 91.3±4.9*1,2 101.3±3.8*1,2 77.7±3.2*2-4
Factor Н ng/ml 39.7±1.0 39.5±1.5 40.5±1.1 39.5±0.5 41.9±0.7
С1-inh. ng/ml 288.5±3.0 272.5±2.3*1 278.8±2.2*1 291.2±2.8*2,3 302.2±4.4*1-4
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the altered parameters under study, in these conditions 
pharmacotherapy with using polyoxidonium has the best 
corrective effect.
Further, the effectiveness of incorporating glutoxime 
and polyoxidation into complex pharmacotherapy in case 
of CCI-II was studied.
In patients with CCI-II prior to treatment, in blood 
plasma there was found an  increase in the the level of all 
the cytokines tested: pro-inflammatory (TNFα, IL-1β, IL-
6, IL-8, IL-17 and IL-18), anti-inflammatory (IL-4 , IL-10 
and IL-1RA), IFNγ, IL-2 and G-CSF. The treatment, in-
cluding ceraxon and mexicor, normalized the concentrati-
on of IL-1β, reduced but not the values of the healthy do-
nors, the content of other pro-inflammatory cytokines and 
G-CSF, even more increased the concentration of IFNγ 
and anti-inflammatory cytokines (IL-4 and IL-1RA), 
without affecting the high levels of IL-10 and IL-2. The 
incorporation of glutoxime into complex pharmacothe-
rapy, in comparison with the previous group of patients, 
normalized the content of IL-17 and G-CSF, shifted aside, 
but not to the values of the healthy donors, the concen-
tration of TNFα, IL-6, IL-8, IL-18, even more increased 
the level of IL-10, without affecting the concentration of 
the remaining cytokines under study. In the patients trea-
ted with polyoxidonium, in comparion with glutoxim, the 
content of anti-inflammatory cytokines IL-10 and IL-1RA 
even more increased and the concentration of IL-6, IL-8, 
IL-18 and IL-2 moved towards the norm (Table 12).
In the blood plasma of the patients with CCI-II before 
the treatment, there was found a decrease in the content of 
C3 and C5-components and inhibitors of the complement 
system (C1-inhibitor and factor H), an increased level of 
C3a and C5a components, whereas the C4 level remained 
within the normal range. After including ceraxon and 
mexicor into pharmacotherapy, the concentration of the 
C3a-component of the complement and the factor H inhi-
bitor was normalized, the levels of C3, C5 and C5a com-
plement components shifted towards the values of the 
healthy donors. Inclusion of immunomodulating glutoxim 
additionally into the pharmacotherapy scheme, in compa-
rison with ceraxon and mexicor, normalized the content 
of the C3 and C5 components of the complement and the 
C1-inhibitor in the blood plasma of the patients. The use of 
polyoxidonium, in comparison with glutoxim, additional-
ly increased the concentration of inhibitors of the comple-
ment system (C1 inhibitor and factor H) (Table 13).
Studying functional metabolic activity of peripheral 
blood neutrophils showed no changes in activity and in-
tensity of phagocytosis (PI, PN and PAI) compared with 
the healthy donors and an increase in the studied parame-
ters of the activity of oxygen-dependent polymorphonu-
clear leukocyte systems (NBT-sp, NBT-st, FR) except for 
SI. After using ceraxon and mexicor in the treatment, the 
indices of the functional-metabolic activity of neutrophils 
did not change. Including immunomodulators glutoxim 
or polyoxidonium in the pharmacotherapy scheme nor-
Table 10. Functional-metabolic activity of blood neutrophils in CCI-I when using glutoxime and polyoxidonium (M±m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-1
Before treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
PI % 7.5±0.4 9.9±0.1*1 9.9±0.3*1 9.0±0.2*1-3 8.6±0.5*1-3
PN abs. 25.1±2.4 26.7±1.1 23.2±2.7 22.0±2.4 26.1±3.1
PAI - 3.8±0.6 2.7±0.1*1 2.4±0.3*1 2.5±0.2*1 3.2±0.3*2-4
NBT-sp % 17.6±2.3 16.8±1.1 13.3±2.7 13.2±1.4 17.5±3.2
NBT-st % 82.8±2.3 79.1±1.7 79.5±4.1 83.0±3.5 85.2±5.7
FR % 7.9±0.4 7.2±0.3 7.8±0.8 6.9±0.9 7.6±0.9
SI - 6.6±0.4 5.7±0.5 6.3±0.9 5.7±0.8 6.4±0.9
Table 11. Neuropsychic status in CCI-I when using glutoxim and polyoxidonium (M±m)
Parameters
1 2 3 4 5
Healthy
CCI-1
Before 
treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
Subjective disorders 0.4±0.02 2.52±0.05*1 1.72±0.09*1,2 0.94±0.03*1-3 0.5±0.08*2,3
Neurological symptom 0 1.45±0.04*1 1.09±0.08*1,2 1.04±0.04*1,2 0.62±0.02*1-4
Cognitive deterioration on GDR scale 0.15±0.01 1.85±0.06*1 1.41±0.13*1,2 1.33±0.03*1,2 1.09±0.05*1-4
Сognitive deterioration on Monreal scale 27.1±0.3 21.3±0.4*1 24.58±0.6*1,2 26.34±0.46*2,3 26.51±0.57*2,3
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malizes NBT-sp and reduces, but not to the level of the 
healthy donors’ indicators, NBT-st and FR, without affec-
ting SI (Table 14).
The use of ceraxon and mexicor in the pharmacothe-
rapy of patients with CCI-II corrected, but significantly 
not to the level of the healthy donors, all the indicators of 
neuropsychiatric status: the total score of intensity of sub-
jective disorders and neurologic symptomsto to 1.7±0.1 
and 1.65±0.12, respectively; the total score on the GDR 
scale and the Montreal scale to 1.9±0.1 and 24.0±0.71. 
The addition of glutoxim to ceraxon and mexicor, brought 
even closer to the values of the healthy donors the scores 
characterizing subjective disorders (1.21±0.09), neurolo-
gic symptoms (1.4±0.04) and cognitive impairment on the 
GDR scale (1.61±0,13), without affecting the indicators 
of cognitive impairment according to the Montreal scale 
(24.31±0.71). More positive clinical dynamics is obser-
ved when using together ceraxon, mexicor and polyoxi-
donium, as in patients with CCI-ΙΙ, when this treatment 
regimen was applied, there was a more evident correction 
towards the indicators of the healthy donors of the total 
score of subjective disorders, neurological symptoms and 
cognitive impairments on the GDR scale to 0.86±0.09, 
1.18±0.08 and 1.38±0.49, respectively (Table 15).
Futher, the comparative effectiveness of the applied 
schemes of pharmacological correction of immune and 
clinical disorders in CCI stage I and II associated with 
AH was carried out. 
In a quantitative comparison of the number of distur-
bed immunological parameters under study, it was found 
that, in case of CCI-I before the treatment, the values of 
19 (73.3%) of the parameters under study were different 
from the norm; besides, it was found out that 26.9% of ex-
changing parameters had the first degree of disorders, and 
stage II and III, respectively 15.4% and 30.8% of them. 
After using ceraxon and mexicore, 57.7% of the indices 
remained disturbed (19.2%, 11.5% and 26.9% had I, II 
and III degrees of disorders, respectively). After using ce-
Table 12. Cytokine spectrum of blood plasma in patients with CCI II stage before treatment with glutoximomie and polyoxidonium (M±m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-II
Before 
treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
IL-4 pkg/ml 0.4±0.04 8.0±0.3*1 13.8±1.4*1,2 14.8±1.7*1,2 14.1±1.3*1,2
IL-10 pkg/ml 2.7±0.13 3.9±0.1*1 4.1±0.1*1 6.8±0.3*1-3 8.3±0.6*1-4
IL-1RA pkg/ml 137.7±1.7 167.8±1.6*1 178.0±3.3*1,2 177.2±3.1*1,2 196.7±3.8*1-4
TNFα pkg/ml 2.9±0.07 13.5±0.4*1 7.8±0.3*1,2 5.9±0.3*1-3 5.5±0.2*1-3
IL-17 pkg/ml 8.7±0.2 22.6±0.9*1 15.3±0.7*1,2 8.9±0.4*2,3 8.3±0.5*2,3
IL-18 pkg/ml 47.6±2.1 135.1±5.0*1 96.8±5.2*1,2 67.4±4.3*1-3 52.8±2.7*1-4
IL-1β pkg/ml 5.3±0.2 11.3±0.3*1 5.2±0.7*2 5.7±0.2*2 5.4±0.2*2
IL-6 pkg/ml 2.4±0.09 14.2±0.5*1 10.5±0.7*1,2 7.4±0.9*1-3 3.9±0.07*1-4
IL-8 pkg/ml 1.8±0.06 16.2±0.7*1 11.0±0.8*1,2 8.3±0.9*1-3 2.5±0.05*1-4
IFNγ pkg/ml 15.6±0.3 23.6±0.7*1 28.6±0.8*1,2 27.4±1.3*1,2 35.8±1.9*1,2
IL-2 pkg/ml 0.14±0.02 6.8±0.4*1 7.8±1.3*1 7.4±0.8*1 2.7±0.8*1-4
G-CSF pkg/ml 12.3±1.0 23.6±1.1*1 20.2±2.2*1,2 15.2±2.1*2,3 14.3±1.0*2,3
Table 13. Complement system in patients with CCI II stage before treatment with glutoxim and polyoxidonium (M±m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-II
Before treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
С3 mg/dl 82.2±1.5 65.1±2.4*1 72.4±1.8*1,2 78.9±2.6*2,3 81.2±2.4*2,3
С
4
ng/ml 24.0±0.5 25.8±0.7 24.8±1.2 26.8±1.6 25.3±1.3
С5 mg/dl 0.1±0.01 0.05±0.005*1 0.07±0.004*1,2 0.1±0.01*2,3 0.09±0.01*2,3
С
3а
mg/dl 38.2±2.1 47.3±1.9*1 39.9±2.7*2 42.4±2.8*2 42.5±2.5*2
С
5а
ng/ml 78.4±3.5 127.3±4.2*1 105.6±7.8*1,2 99.5±5.8*1.2 101.3±4.3*1,2
Factort Н ng/ml 39.7±1.0 36.8±0.7*1 40.7±2.6*2 41.9±1.0*2 55.6±2.4*1-4
С1-inh. ng/ml 288.5±3.0 274.7±2.4*1 273.3±2.6*1 291.2±2.6*2,3 306.4±3.2*1-4
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raxon, mexicor and glutoxim, 38.5% remained different 
from the values of the healthy donors (7.7%, 11.5% and 
19.2% had I, II and III degrees of disorders, respective-
ly). The most effective scheme of pharmacotherapy was 
found to be a combination of ceraxon, mexicor and po-
lyoxidonium, since 26.9% of the indicator happened to 
be changed, and 7.7%, 7.7% and 11.5% had I, II and III 
degrees of disorders, respectively (Table 16).
Basic pharmacotherapy in this case is considered to be 
the least effective combination of ceretone+actovegin, ap-
plied simultaneously with the described treatment regimens. 
At the same time, the combination of ceraxon and mexicor 
did not differ from ceritone and actovegin in terms of labo-
ratory efficacy in case of CCI-I, and the ceraxon+mexicor+-
polyoxidonium scheme (61 points) was more preferable 
than ceraxon+mexicor+glutoxim (28 points) (Table 17).
In a quantitative comparison of the number of distur-
bed immunological parameters under study, it was found 
out that in case of CCI-II before the treatment, 80.8% of 
the indicators under study were different from the values 
of the norm; and with that, it was discovered that I and II 
degrees of disorders had 19.2% and III degree – 42.3% 
of the indicators. After using ceraxon and mexicore, 
73.1% of the indicators (for I and II degrees – 19.2% 
each and for III – 34.6%) remained disturbed. After 
using ceraxon, mexicor and glutoxim, 50.0% remained 
different from the indicators of the healthy donors (for I, 
II and III degrees – 19.2%, 3.8% and 26.9%, respective-
ly). After combining ceraxon, mexicor and polyoxidoni-
um, 57.7% of the parameters were changed, with that I, 
II and III degree of disorders had 19.2% of parameters 
each (Table 18).
Table 16. Comparative immunological efficacy of different schemes of pharmacological therapy for CCI-I
Experimental conditions
Indicators different from 
those of healthy donors
Changed indicators according to degree of disorder
I II III
total % total % total % total %
Before treatment 19 73.1 7 26.9 4 15.4 8 30.8
Ceraxon + Mexicore 15 57.7 5 19.2 3 11.5 7 26.9
Ceraxon + Mexicor + Glutoxime 10 38.5 2 7.7 3 11.5 5 19.2
Ceraxon + Mexicor + Polyoxidonium 7 26.9 2 7.7 2 7.7 3 11.5
Table 14. Functional-metabolic activity of blood neutrophils in patients with CCI stage II before treatment with glutoximomie 
polyoxidonium (M ± m)
Parameters Unit
1 2 3 4 5
Healthy
CCI-II
Before  
treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
FI % 82.8±2.3 78.9±2.8 84.1±6.2 80.6±5.1 89.7±9.0
FN abs. 7.9±0.4 7.8±0.4 7.9±1.1 7.8±0.7 8.9±1.2
IAF - 6.6±0.4 6.4±0.3 6.8±1.2 6.3±0.6 6.8±0.8
NBT-sp. % 7.5±0.4 11.0±1.2*1 12.1±1.3*1 8.4±0.9*2,3 8.1±0.6*2,3
NBT-st % 25.1±2.4 37.5±2.9*1 39.6±4.0*1 29.5±1.2*1-3 29.6±2.2*1-3
FRN % 17.6±2.3 26.5±2.1*1 27.4±4.1*1 21.1±1.7*1-3 21.5±2.3*1-3
ISN - 3.8±0.6 3.4±0.3 3.9±0.8 3.5±0.6 3.7±0.3
Table 15. Comparative analysis of indicators of neuropsychiatric status when treating patients with CCI-II with various schemes of 
pharmacological therapy (M±m)
Parameters
1 2 3 4 5
Healthy
CCI-II
Before  
treatment
After treatment
Ceraxon + 
Mexicore
Ceraxon + 
Mexicor + 
Glutoxime
Ceraxon + 
Mexicor + 
Polyoxidonium
Subjective disorders 0.4±0.02 2.85±0.06*1 1.7±0.1*1,2 1.21±0.09*1-3 0.86±0.09*1-4
Neurological symptom 0 2.3±0.04*1 1.65±0.12*1,2 1.4±0.04*1-3 1.18±0.08*1-4
Cognitive deterioration on GDR scale 0.15±0.01 2.75±0.05*1 1.9±0.1*1,2 1.61±0.13*1-3 1.38±0.06*1-4
Сognitive deterioration on Monreal scale 27.1±0.3 18.8±0.7*1 24.0±0.71*1,2 24.31±0.71*1,2 24.35±0.49*1,2
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In terms of laboratory efficacy in case of CCI-II, the 
combination of ceraxon and mexicor was slightly more 
effective than that of ceriton and actovegin, and the ce-
raxon+mexicor+glutoxim scheme (42 points) was actual-
ly at the same level as the ceraxon+Mexicor+polyoxido-
nium scheme (34 points) (Table 18).
Discussion
Given that one of the main causes of the immune in-
flammatory reaction, which is of a metabolic nature, is 
hypoxia, an increase, that was detected, of the content 
of pro-inflammatory cytokines and chemokines (TNFα, 
IL IL-6, IL-6, IL-8, IL-17, IL-18) with a compensatory 
increase in the concentration of anti-inflammatory cyto-
kines (IL-10, IL-1RA, IL-4) in the systemic circulation 
of patients with CCI-I and CCI-II reflects the reaction of 
resident and recruited cells of innate immunity and epit-
helium to molecular patterns associated with a damage 
(Zurochka et al. 2013, Yarilin 2010, Loktionov et al. 
2015, Pigarevskyy et al. 2014, Lukens et al. 2012, Spen-
ceret al. 2014).
TNFα, the primary mediator of inflammation involved 
in the pathogenesis of most infectious and immunopatho-
logical diseases, coordinates an inflammatory response 
and the cytokine cascade (IL-1β, IL-6, IL-8). IL-1,the 
main mediator of the development of the local inflamma-
tory reaction, it is one of the key factors in developing 
an immune response, including in case of in sterile in-
flammation, participates in the transformation of local 
inflammation into a systemic inflammation, stimulates 
the synthesis of IL-6, TNFα, IL -12, IL-8, IL-23, IFNγ, 
activates lymphocytes, expression of adhesion molecules 
on endotheliocytes, increases NO synthase activity, parti-
cipates in the production of acute inflammation proteins, 
and demonstrates neuroregulatory activity. Massive pro-
duction of IL-1β develops with ischemia, and blockade of 
signaling cascades associated with IL-1 can significantly 
reduce tissue damage and production of other cytokines. 
IL-6, a broad-spectrum pro-inflammatory cytokine, par-
ticipates in the induction of almost the entire complex 
of local manifestations of inflammation, influences the 
migration of phagocytes by increasing the production of 
CC-chemokines that attract monocytes and macrophages 
and weakening the production of CXC-chemokines that 
attract neutrophils, induces the production of acute pha-
se proteins by hepatocytes, and increases the activity of 
cytotoxic T-lymphocytes. The pro-inflammatory chemo-
kine IL-8 provides extravasation of neutrophils and their 
directed migration to the inflammatory focus, where its 
sources are macrophages of the inflammatory focus and 
endothelial cells of the vessels in the inflammatory zone. 
The IL-8 produced by them provides for attracting neu-
trophils to the vascular wall, activating their integrins and 
emigration of a cell from the vessel. In addition, the che-
mokine stimulates the production of cytokines by mon-
onuclears and exercises an angiogenic effect ( 
Yarilin 2010, Lukens et al. 2012, Chen et al. 2010).
IL-17 has a pro-atherogenic pro-inflammatory effect 
through activating the release of IL-1, IL-6, IL-8, TNFα, 
IFNγ, G-CSF by immunocytes and endothelial cells; in-
duces the formation of VEGF, angiogenic factors; regu-
lates the number of neutrophils; enhances adhesion and 
penetration of monocytes and neutrophils into the arterial 
wall, but at the same time there is evidence of the stimu-
lating effect of IL-17 on the production of anti-inflamma-
tory cytokines. IL-18 activates monocytes and macropha-
ges, initiates apoptosis processes, induces the production 
of IL-8 and IFNγ in T-lymphocytes, macrophages and 
NK cells, promotes the differentiation of T-lymphocytes 
Table 17. Own corrective effects of various combinations of ceraxon, mexicor, glutoxime and polyoxidonium in case of CCI-I and CCI -I
Pharmacological treatment regimens Total score of correction indicators
CCI-I
Ceraxon +Mexicore 0
Ceraxon +Mexicor +Glutoxime 28
Ceraxon +Mexicor +Polyoxidonium 61
CCI-II
Ceraxon +Mexicore 8
Ceraxon +Mexicor +Glutoxime 42
Ceraxon +Mexicor +Polyoxidonium 34
Table 18. Comparative immunological efficacy of various regimens of pharmacological therapy for CCI-II 
Experimental conditions
Indicators different from 
those of healthy donors
Changed indicators according to degree of disorder
I II III
total % total % total % total %
Before treatment 21 80.8 5 19.2 5 19.2 11 42.3
Ceraxon + Mexicore 19 73.1 5 19.2 5 19.2 9 34.6
Ceraxon + Mexicor + Glutoxime 13 50.0 5 19.2 1 3.8 7 26.9
Ceraxon + Mexicor + Polyoxidonium 15 57.7 5 19.2 5 19.2 5 19.2
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into the Th1 cell line, which underlies the development of 
pro-inflammatory and pro-atherogenic Th1 immune res-
ponse, and destabilizes the atherosclerotic plaque (Chen 
et al. 2010, Simbirtsev 2004, Khaden et al. 2009).
One should also note a high-level of IFNγ (effector of 
cellular immune response of inflammatory type) and pro-
longed retention of an increased ratio IFNγ/IL-4 in blood, 
which does not decrease after treating the patients with ei-
ther CCI-I or CCI-II. This is indicative of activation of IF-
Nγ-producing NK-cells, being lymphoid cells of the inna-
te immune type I (ILC-1), which provide the polarization 
of T-cell differentiation towards the T-helper type 1 (Th1), 
activating macrophages, expressing enzymes responsible 
for forming active forms of oxygen, NO-synthase, and 
the formation of NO. Later, ILC-1 and Th1 synergistical-
ly support mainly the T-cell response (Chen et al. 2007).
In addition, a significant increase in the concentrati-
on of colony-stimutating factor G-CSF and IL-2 was 
found, which also did not decrease after treating the pa-
tients with either CCI-I or CCI-II. G-CSF activates ma-
ture neutrophils and supports the growth of both mixed 
granulocyte-monocyte colonies and individual colonies 
of granulocytes and monocytes/macrophages. IL-2 has a 
pronounced ability to induce the activity of virtually all 
clones of cytotoxic cells, increases the cytolytic function 
of T-killers and NK-cells, activates monocytes and ma-
crophages, thereby increasing the synthesis and secretion 
of pro-inflammatory cytokines, chemokines, colony-sti-
mulating factors GM-CSF and causes the accelerated 
proliferation of T- and B-lymphocytes and the restoration 
of the functional reserve of macrophages ( K e t l i n s k y 
and Simbirtsev 2008, Yarilin 2010, Simbirtsev 2004).
An increase, in both CCI stages, of anti-inflammatory 
cytokines (IL-10, IL-1RA, IL-4) is compensatory in na-
ture, limiting the inflammatory response, whereas at the 
same time a high level of IL-6 and IL-17 can also have 
an anti-inflammatory effect along with a significant incre-
ase in pro-inflammatory cytokines due to stimulating the 
production of IL-10, IL-1RA, and cortisol. With that, a 
significant increase in the level of IL-4 and IL-1Ra should 
be noted before and after treating the patients with CCI-
II, especially when using polyoxidonium in the complex 
pharmacotherapy (Turmova et al. 2014, Karaulov 2008).
It was determined that in patients with CCI-I and CCI-
II, the complement system was activated, with no com-
pensatory increase in factor H inhibitor with a decrease 
in C1-inh, as evidenced by a decrease in the initial com-
ponents of the complement C3 and C5 with an increase in 
the levels of fragments C3a and C5a released through acti-
vation, being active chemotactic and vasodilating factors, 
which have anaphylactogenic activity and participate in 
the reactions of inflammation and hypersensitivity. Mo-
reover, the complement system interacts with other hu-
moral systems activated by inflammatory processes and 
promotes the involvement of these systems into the im-
mune inflammatory response. Finally, the deposition of 
the complement components in the immune complexes 
on biological membranes initiates the development of im-
munopathology due to attracting macrophages and other 
effectors of immune inflammation to the lesion focus (Ya-
rilin 2010, Loktionov et al. 2015, Boyadzhyan et al. 2010, 
Khaitov et al. 2010, Pyokhova et al. 2012, Serebryanaya 
et al. 2015).
When studying the functional metabolic activity of pe-
ripheral blood neutrophils in patients with CCI-I and CCI-
II when they are admitted to hospital, there was found no 
change in the indicators of phagocytosis activity and in-
tensity (FI, FN, and IAF), an increase in NBT-sp. with a 
decrease in ISN in patients with CCI-I and in case of CCI-
II an increase of the majority of the studied parameters 
of the activity of oxygen-dependent polymorphonuclear 
leukocyte systems (NBT-sp., NBT-st., FRN). A distinc-
tive feature of the differences in the CCI stages was that in 
case of CCI-II there was found an increasing the level of 
oxygen-dependent metabolism of polymorphonuclear leu-
kocytes of peripheral blood that was not compensated for 
by the pharmacotherapy applied, which indicated an incre-
ased production of reactive oxygen intermediates resulting 
from a respiratory explosion, which can be possibly con-
sidered as the most important link in the further develop-
ment of inflammation at this stage of CCI. The latter refers 
to the increased value of the indicators of oxygen-depen-
dent activity of circulating neutrophils in case of CCI-II, 
which can be considered as the most important link in the 
further development of inflammation (Karaulov and Kal-
yuzhin 2013, Karaulov et al. 2015, Solovyova et al. 2016).
The principle of treating CCI is to eliminate external 
factors that affect the increase in blood pressure, constant 
antihypertensive therapy and the use of drugs optimizing 
cerebral blood flow, neurotransmitter and metabolic acti-
vities, with pronounced antioxidant and antihypoxic ef-
fects, having a multifactorial effect on the brain tissue and 
creating neurometabolic protection of brain cells from 
ischemia and hypoxia, enhancing reparative processes 
in the brain (Levin et al. 2014, Putilina 2016, Suslina  et 
al. 2011, Putilina 2014, Chukanova and Chukanov 2014, 
Schmidtke and Hull 2005).
Taking into account the results of our evaluation of the 
immunometabolic status in this category of patients, it is 
necessary to use various combinations of nootropic, anti-
oxidant and immunomodulating drugs in a comprehensi-
ve pharmacological therapy.
The mechanism of the energy-correcting action of 
mexicor (2-ethyl-6-methyl-3-hydroxypyridine succinate 
– EMHPS) is connected with a specific influence of suc-
cinate on energy metabolism, which, in case of hypoxia, 
when entering the intracellular space, can get oxidized in 
Krebs cycle. In case of hypoxia, succinate supports acti-
vity of FAD-dependent link of the Krebs cycle, catalyzed 
by succinate dehydrogenase, and provides enhanced com-
pensatory activation of aerobic glycolysis and reduced in-
hibition of oxidative processes in the TCA cycle which 
increases the content of ATA and creatine phosphate in 
anaerobic conditions, activates the energy-synthesizing 
functions of mitochondria, which, under hypoxic condi-
tions, allows maintaining energy production in the cell 
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for a certain time period. At the heart of the antihypoxic 
and a number of systemic effects of succinate may lie its 
proven ability to influence protein HIF-1, which ensures 
the induction of the genetic apparatus responsible for 
forming the structural basis for long-term adaptation to 
hypoxia. The presence of 3-hydroxypyridine in the struc-
ture of mexicor facilitates the intracellular penetration of 
succinic acid and provides for a set of its antioxidant and 
membranotropic effects and the ability to reduce glutama-
te excitotoxicity, to modulate the function of receptors, 
which fundamentally distinguishes these drugs from other 
medications containing succinic acid (Nikolaev and Bys-
trova 2008, Okovityy et al. 2012, Evglevsky et al. 2013, 
Novikov and Levchenkova 2013, Tikhonova et al. 2016).
Ceraxon (citicoline, cytidine-5-diphosphocholine, cyti-
dine diphosphate) after absorption breaks down into cho-
line and cytidine, which easily penetrate the BBB, and 
after a number of chemical reactions it is converted into 
cytide-dintriphosphate in brain neurons, gets distributed 
in the cerebral cortex, white matter, subcortical nuclei, the 
cerebellum, becoming part of the structural phospholipids 
of cytoplasmic and mitochondrial membranes. The clinical 
effects of the drug in conditions of cerebral ischemia are 
largely related to its antioxidant and reparative properties. 
Reducing but not suppressing the activity of phospholipa-
se A2, citicoline restores the content of arachidonic acid 
of phosphatidyl-choline, which helps stabilize the mem-
brane, resulting in an increased speed of SOD binding to 
substrates and in improving its activity. By promoting the 
accumulation of non-enzymatic component of the anti-oxi-
dant system, α-tocopherol, on the cell membrane, citicoline 
reduces the formation of hydroperoxides of fatty acid and 
peroxy radicals involved in generating oxidatively modi-
fied phospholipids. The choline released from citicoline can 
get metabolized to glutathione, which is one of the main 
endogenous antioxidant defense components in the brain, 
removes hydrogen peroxide and lipid peroxides and pre-
vents the inactivation of glutathione reductase (Solovyova 
et al. 2016, Putilina 2014, Mendelevich 2016, Adibhatla 
and Hatcher 2005, Lee et al. 2009, Davies and Guo 2014).
So, by taking into account the literature and the results 
of our studies given above, there is little doubt about the 
participation of immune mechanisms in the formation and 
development of CCI, which made it necessary to use im-
munomodulators, in particular glutoxim and polyoxidoni-
um, to correct immune disorders (Gusev and Chukanova 
2015, Gavrilyuk et al. 2016, Karaulov  2008, Otman et al. 
2015, Konoplya et al. 2015). 
In a quantitative comparison of the total number of 
disturbed immunological and metabolic parameters un-
der study, it was found out that in case of CCI-I before 
treatment 84.4% of the studied parameters were different 
from the normal values, with that 57.8% of the parameters 
were found to have II and III degree of disorders requi-
ring correction. After treatment with ceretone and actove-
gin, 71.1% of the laboratory parameters were found to be 
changed, with the total of 40.0% with II and III degrees of 
disorders. After using ceraxon and mexicor, 60.0% of the 
indicators remained disrupted (40.0% of which with gra-
de II and grade III disorders). After introducing glutoxime 
into the cexaxon+mexicor regimen, 44.4% of the indica-
tors remained different from the values of healthy donors 
(28.9% of which with grade II and grade III disorders). 
The combination of ceraxon, mexicor and polyoxidonium 
showed great effectiveness, as 24.4% of the parameters 
were found to be changed, and 15.6% of the parameters 
had II and III degree of disorders.
The pronounced corrective effects of glutoxim are 
most likely provided by its selective effect on the functi-
onal metabolic activity of monocytes/macrophages, neu-
trophils, and NK-cells, by increasing or decreasing their 
activity depending on the initial values. In addition, the 
drug has pronounced anti-inflammatory, antioxidant and 
regenerative effects (Spits et al. 2013). 
The effects of polyoxidonium, in our studies, primarily 
are linked to its pronounced immunocorrective action on 
immunocompetent cells, by increasing or decreasing their 
activity depending on the initial values, thereby reducing 
pathological changes in neurons and microglia. Besides, 
the drug has a pronounced anti-inflammatory, antitoxic, 
antioxidant, membrane-stabilizing and regenerative acti-
ons.  (Konoplya  et al. 2015, Karaulov  2008, Benarroch 
2007, Spits et al. 2013).
Conclusion
1. In case of chronic brain ischemia of I and II stages ac-
companied by II-degree hypertension, in case of both 
stages similar changes in the parameters of the system 
of cytokines and complement were found, the changes 
being more pronounced with II stage: an increase in the 
concentration of proinflammatory (TNFα, IL-1β, IL-6, 
IL-8 , IL-17, IL-18), anti-inflammatory cytokines (IL-
4, IL-10, IL-1RA), IFNγ, IL-2 and G-CSF cytokines, 
reduction of C3 and C5-components of the complement, 
C1-inhibitor, and an increase in C3a and C5a-compo-
nents.
2. At chronic ischemia of the brain of I and II stages, no 
changes were found in the indicators of activity and 
intensity of circulating neutrophils phagocytosis; in ca-
ses of II stage of disease, the activity of oxygen-depen-
dent systems of poly-morphogenic nuclear leukocytes 
was increased, which can be considered as the most 
important link in the further development of immune 
inflammation.
3. In the comparative analysis of the immune status para-
meters in patients with CCI studied against various tre-
atment regimens used in the study, it was found out that 
in cases of CCI-I, according to immune and clinical 
efficacy in ascending order, the drugs under study were 
arranged in the following order: ceraxon+mexicor ® 
ceraxon+mexicor+glutoxim ® ceraxon+mexicor+po-
lyoxidonium.
4. In cases of CCI-II, the increasing laboratory efficacy 
of the combinations used was the following: ceraxon+-
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mexicor ® ceraxon+mexicor+polyoxdonium = ce-
raxon+mexicor+glutoxim.
5. In cases of CCI-II, according to increasing clinical ef-
ficacy, the treatment regimens applied were arranged 
in the following order: by subjective disorders and 
neurological symptoms: ceraxon+mexicor ® ceraxon+-
mexicor+glutoxim ® ceraxon+mexicor+polyoxidoni-
um, and by cognitive disorders: ceraxon+mexicor ® 
ceraxon+mexicor+glutoxim = (on Montreal scale) and 
® (on GDR scale) ceraxon+mexicor+polyoxidonium.
Recommendations
1. In the complex pharmacotherapy of chronic ischemia 
of the brain of I stage accompanied by hypertension, to 
recommend the use of a combination of ceraxon (1000 
mg intravenously, stream infusion, in 24 hours No. 14), 
mexicor (200 mg after 24 hours, intravenously, stream 
infusion for 5 minutes, No.14), and polyoxidonium (6 
mg, intramuscularly, 8 times (daily for the first 2 days, 
then every other day).
2. In the complex pharmacotherapy of chronic cerebral 
ischemia of the brain of II stage accompanied by hy-
pertension, to recommend the use of a combination of 
ceraxon (1000 mg intravenously, stream infusion, after 
24 hours, No. 14), mexicor (200 mg after 24 hours, 
intravenously, stream infusion for 5 minutes, No. 14) 
with glutoxim (30 mg in 1 ml of 3% solution, intra-
muscularly, in 24 hours № 14) or polyoxidonium (6 
mg, intramuscularly, 8 times (daily for the first 2 days, 
then every other day).
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